15.93
1.30%
-0.2099
Assembly Biosciences Inc stock is traded at $15.93, with a volume of 26,353.
It is down -1.30% in the last 24 hours and down -12.66% over the past month.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
See More
Previous Close:
$16.14
Open:
$16.29
24h Volume:
26,353
Relative Volume:
0.93
Market Cap:
$99.63M
Revenue:
-
Net Income/Loss:
$-61.23M
P/E Ratio:
-9.7731
EPS:
-1.63
Net Cash Flow:
$22.49M
1W Performance:
-2.92%
1M Performance:
-12.66%
6M Performance:
+9.64%
1Y Performance:
+84.38%
Assembly Biosciences Inc Stock (ASMB) Company Profile
Name
Assembly Biosciences Inc
Sector
Industry
Phone
(833) 409-4583
Address
TWO TOWER PLACE, SOUTH SAN FRANCISCO
Compare ASMB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ASMB | 15.93 | 99.63M | 0 | -61.23M | 22.49M | -1.63 |
VRTX | 467.02 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 759.96 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 564.96 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 231.32 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.42 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-13-21 | Initiated | H.C. Wainwright | Neutral |
Sep-02-21 | Downgrade | William Blair | Outperform → Mkt Perform |
Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Nov-06-20 | Downgrade | Jefferies | Buy → Hold |
Oct-19-20 | Initiated | Truist | Buy |
Oct-16-19 | Initiated | Mizuho | Buy |
Nov-19-18 | Initiated | Leerink Partners | Outperform |
Oct-08-18 | Upgrade | B. Riley FBR | Neutral → Buy |
Aug-08-18 | Initiated | Robert W. Baird | Outperform |
Apr-13-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Jan-05-18 | Initiated | B. Riley FBR, Inc. | Neutral |
Nov-08-17 | Initiated | Jefferies | Buy |
May-30-17 | Initiated | Chardan Capital Markets | Buy |
View All
Assembly Biosciences Inc Stock (ASMB) Latest News
(ASMB) Pivots Trading Plans and Risk Controls - Stock Traders Daily
ARMISTICE CAPITAL, LLC Adjusts Stake in Assembly Biosciences Inc - GuruFocus.com
What is HC Wainwright's Forecast for ASMB FY2024 Earnings? - MarketBeat
Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Down 51.2% in October - MarketBeat
Analysts Just Slashed Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Numbers - Simply Wall St
Bearish: Analysts Just Cut Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue and EPS estimates - Yahoo Finance
Analyzing Taysha Gene Therapies (NASDAQ:TSHA) & Gilead Sciences (NASDAQ:GILD) - Defense World
Assembly Biosciences: Q3 Earnings Snapshot - CTPost
Assembly Biosciences initiates at-the-market equity program - Investing.com India
Assembly Biosciences Inc (ASMB) Reports Q3 2024 Revenue of $6.8M, GAAP EPS Loss of $1.51, Misses Estimates - GuruFocus.com
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates - The Manila Times
Marquis Who's Who Honors Jonathan Colon, PhD, for Expertise in Biotechnology - 24-7 Press Release
Assembly Biosciences (NASDAQ:ASMB) Stock Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
When (ASMB) Moves Investors should Listen - Stock Traders Daily
Baker Lab’s AI-Driven Antibody Cage Technology Unlocked as Archon Biosciences - Genetic Engineering & Biotechnology News
Short Interest in Assembly Biosciences, Inc. (NASDAQ:ASMB) Declines By 7.9% - MarketBeat
Assembly Biosciences (NASDAQ:ASMB) Share Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
(ASMB) Investment Analysis and Advice - Stock Traders Daily
Microbiome Manufacturing Market Poised for Robust Growth at 15.4% CAGR by 2031 - WhaTech
Assembly Biosciences (NASDAQ:ASMB) Shares Pass Above 200-Day Moving AverageTime to Sell? - MarketBeat
Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Update - MarketBeat
Assembly Biosciences, Inc.'s (NASDAQ:ASMB) market cap surged US$16m last week, individual investors who have a lot riding on the company were rewarded - Simply Wall St
Assembly Biosciences sees major stock purchase by investor Alexander Schornstein By Investing.com - Investing.com Canada
Alexander Schornstein Purchases 10,000 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) Stock - MarketBeat
Assembly Biosciences (NASDAQ:ASMB) Share Price Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat
Assembly Biosciences CEO sells shares worth $2,917 to cover taxes By Investing.com - Investing.com South Africa
Assembly Biosciences CEO sells shares worth $2,917 to cover taxes - Investing.com India
How To Trade (ASMB) - Stock Traders Daily
Assembly Biosciences executive sells shares worth $2,325 By Investing.com - Investing.com South Africa
Assembly Biosciences executive sells shares worth $2,325 - Investing.com India
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year? - Yahoo Finance
Assembly Biosciences, Inc. (NASDAQ:ASMB) Sees Significant Growth in Short Interest - MarketBeat
Armistice Capital LLC Makes New Investment in Assembly Biosciences, Inc. (NASDAQ:ASMB) - MarketBeat
Investment Analysts’ Updated EPS Estimates for September 24th (AB, AG, AIOT, AIR, AMWL, ASMB, BAG, BDTX, BHVN, BIIB) - Defense World
Assembly Biosciences (NASDAQ:ASMB) Rating Reiterated by HC Wainwright - MarketBeat
(ASMB) Trading Signals - Stock Traders Daily
Assembly Biosciences advances genital herpes treatment study - Investing.com
Assembly Biosciences' Investigational Herpes Treatment Shows Antiviral Efficacy, Safety In Healthy Participants - AOL
Tonight | The Assembly on ABC and ABC iview S1E6 - TV Central
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting - EIN News
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 - StockTitan
The Assembly: Sept 24 - TV Tonight
Jefferies sees upside in Assembly Biosciences stock ahead of key Phase IA data - Investing.com
Schlumberger Limited (NYSE:SLB) Holdings Lifted by Richardson Financial Services Inc. - Defense World
Assembly Biosciences (NASDAQ:ASMB) Upgraded to Buy by Jefferies Financial Group - MarketBeat
Assembly Coffee closing after two years in Ballard - My Ballard
Assembly Biosciences Inc Stock (ASMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):